# A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)

> **NCT00100152** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 50 (—)

## Conditions studied

- Leukemia, Lymphoblastic, Acute, T-cell
- Myelogenous Leukemia
- Chronic Lymphocytic Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** MK0752, (Notch Inhibitor)

## Key facts

- **NCT ID:** NCT00100152
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-02
- **Primary completion:** 2006-09
- **Final completion:** 2006-10
- **Target enrollment:** 50 (—)
- **Last updated:** 2015-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00100152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00100152, "A Notch Signalling Pathway Inhibitor for Patients With T-cell Acute Lymphoblastic Leukemia/Lymphoma (ALL)(0752-013)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00100152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*